A pivotal trial to investigate the efficacy of affinity enhanced T-cell therapy targeting NY-ESO (NY-ESO-1/LAGE-1-specific T-cells) in synovial sarcoma

Trial Profile

A pivotal trial to investigate the efficacy of affinity enhanced T-cell therapy targeting NY-ESO (NY-ESO-1/LAGE-1-specific T-cells) in synovial sarcoma

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary)
  • Indications Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2016 According to an Adaptimmune media release, initiation of this trial has been delayed until mid-2017.
    • 22 Apr 2016 According to Adaptimmune media release, company plans to start this study in 4Q of 2016/1Q 2017.
    • 10 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top